First-developed ACE inhibitor — short-acting, sulfhydryl-containing. Faster onset than enalapril (active drug, no prodrug) supports use in hypertensive urgency. Sulfhydryl group may contribute to higher rash + dysgeusia (metallic taste) than newer ACEi.
Half-Life & Elimination Curve (PO: 2h)
Plasma (PO)t½ Decay (2h)
0×t½0h100%(0.367 mg/L)
1×t½2h50%(0.183 mg/L)
2×t½4h25%(91.7 µg/L)
3×t½6h12.5%(45.8 µg/L)
4×t½8h6.3%(22.9 µg/L)
5×t½10h3.1%(11.5 µg/L)
Elimination t½2h (PO)
Rate Constant (ke)0.347 h⁻¹
Time to Peak (Tmax)1.33h
Est. Peak (Cmax)0.367 mg/L
Clearance (CL)19.4 L/h
97% Washout (5×t½)10h
Dosing Guidelines
Oral (PO): Typical 50 mg (Range: 12.5–150 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 65% · Volume of Distribution (Vd): 56 L · Absorption (ka): 1.4 h⁻¹ (t½ka ≈ 30m) [PMID 3292102]